DexCom (DXCM) is back in focus after expanded insurance reimbursement opened a large new market for its continuous glucose monitoring systems, giving more type 2 non insulin patients access to its products.

Despite the reimbursement expansion opening up a fresh pool of type 2 non insulin users, DexCom’s recent share price performance has been weak, with a 30 day share price return of 7.88% and a 1 year total shareholder return of 14.08%, pointing to fading momentum even as the longer term story around market access and earnings per share growth remains in focus.

If this kind of healthcare technology story interests you, it may be worth widening the search and checking out 33 healthcare AI stocks

With DexCom shares showing a 14.08% 1 year total shareholder return, alongside double digit annual revenue and net income growth, the key question now is simple: is this weakness a reset that leaves upside on the table, or is the market already pricing in every step of future growth?

Most Popular Narrative: 29.1% Undervalued

DexCom's most followed narrative points to a fair value of $86.88 versus the last close at $61.57, putting the spotlight firmly on future execution and earnings power.

The recent expansion of insurance reimbursement for type 2 non-insulin diabetes patients, now covering nearly 6 million lives across the three largest U.S. PBMs, opens a large, previously untapped segment of DexCom's addressable market, driving new patient growth and supporting robust multi-year revenue expansion.

Growing global recognition of CGM efficacy, with recent clinical trial evidence and expanded coverage in international markets (e.g., France, Japan, and Ontario, Canada), positions DexCom to penetrate underpenetrated regions and diversify revenue streams, creating sustainable top-line growth.

Want to see what underpins that gap between price and fair value? The narrative leans heavily on compounding revenue, expanding margins, and a richer earnings base that supports a premium future multiple.

Result: Fair Value of $86.88 (UNDERVALUED)

However, this narrative could be challenged if CMS competitive bidding pressures CGM pricing or if rivals gain share with new multi-analyte or non-invasive sensors.

Next Steps

With optimism around rewards and risks now on the table, this is a moment to check the numbers yourself and decide where you stand. To see what others are focusing on, take a closer look at the 4 key rewards

Looking for more investment ideas?

If DexCom has caught your attention, do not stop here. Broaden your watchlist with other focused ideas that could sharpen how you think about risk and return.

• Target potential mispricings by scanning companies that combine quality fundamentals with room for re rating using the 55 high quality undervalued stocks.
• Prioritize resilience and sleep better at night by checking companies that score well on financial strength through the 73 resilient stocks with low risk scores.
• Spot earlier stage opportunities with solid financial underpinnings by reviewing the screener containing 24 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.